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httpcense.Abstract It has been recognized that, in addition to its classical function, vitamin D modulates a
variety of processes and regulatory systems including host defense, inﬂammation, and immunity.
Some authors concluded that there is strong relation between vitamin D serum level and lung func-
tions but others concluded that there is no relation between them.
Aim of the work: To study the role of serum level of 25 hydroxy-vitamin D in COPD patients,
also, assess the serum level of vitamin D dependent LL-37 and IFNc and to study the link between
the three parameters and pulmonary functions in these patients.
Subjects and methods: This study was conducted on 40 persons who were divided into GI, 10
controls and GII, 30 COPD patients. FEV1, serum levels of 25 hydroxy vitamin D, LL-37 and
IFNc were measured.
Results: Serum levels of 25 hydroxy vitamin D and LL-37 were signiﬁcantly decreased in GII as
compared to GI while serum level of IFNc was signiﬁcantly increased in GII as compared to GI and
there was a signiﬁcant positive correlation between vitamin D level and FEV1 and LL-37 level while
there was a negative correlation between it and IFNc level.
Conclusion: Vitamin D level affects pulmonary function in COPD through its effect on LL-37
and IFNc serum level.
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spirometeric data in GI and GII.
GI GII t Test p Value
FVC 96.76 ± 1.73 70.55 ± 6.48 12.632 0.001
FEV1 97.60 ± 1.78 40.83 ± 6.35 27.528 0.001
FEV1/FVC 100.9 ± 2.95 57.61 ± 4.34 29.230 0.001
PEFR 96.31 ± 2.10 61.25 ± 6.85 15.360 0.001
FEF 25–75% 98.07 ± 1.56 61.35 ± 6.71 14.528 0.001
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Figure 1 Mean, standard deviation and statistical analysis of
spirometeric data in GI and GII.Introduction
The role of vitamin D in calcium and bone homeostasis is well
described. In the last years, it has been recognized that, in
addition to its classical function, vitamin D modulates a vari-
ety of processes and regulatory systems including host defense,
inﬂammation, and immunity and repair, especially patients
with lung diseases often have low vitamin D serum level. Epi-
demiological data indicated that low serum level of vitamin D
is associated with impaired pulmonary function, increased
incidence of inﬂammatory infectious or neoplastic diseases
[1]. Recently, the connection between vitamin D status and
COPD has attracted attention [2]. Some authors concluded
that there was a strong relationship between serum level of
vitamin D and lung functions. In contrast, others did not ﬁnd
any relation between them [3]. Cathelicidin LL-37 is the only
member of the cathelicidin family of host defense peptides that
is expressed in humans. It is a linear 37 amino acid peptide
produced from the C-terminus of hCAP18 precursor protein
by a proteolytic cleavage [4]. LL-37 is produced by phagocytic
leucocytes and other cells, it is a major constituent of zurophil-
ic granules of neutrophils, it has direct antimicrobial action
and diverse immuno-modulatory properties [5,6]. Importantly,
the production of LL-37 in human primary monocytes in
response to infection is dependent on 1.25 vit D3 either exog-
enously supplemented in ex vivo systems or naturally present
in human serum [7]. In addition to the widely recognized role
of 1.25 vit D3 in antimicrobial immunity, it is also known to
have anti-inﬂammatory activity, suppressing the intentions of
TNFa, IFNc and IL12 p40 [8]. Thus, the recently established
role of 1.25 vit D3 in LL-37 induction further reinforces the
notion that LL-37, may function in the context of ‘‘non classi-
cal’’, non inﬂammatory responses to infection. Possible contri-
butions of LL-37 to the anti-inﬂammatory activity of the 1.25
vit D3 system remain to be investigated [9].
Aim of the work
Is to study the role of serum level of 25 hydroxy-vitamin D in
COPD patients through the assessment of the serum levels of
vitamin D dependent LL-37 and IFNc and to study the link
between the three parameters and pulmonary functions in
these patients.
Patients and methods
This work included 40 persons collected from the outpatients
chest clinic in the Tanta University hospitals in the period from
February to May 2013 and were divided into two groups.Group I: Included 10 apparently healthy non smoker volun-
teers, 7 males and 3 females, and their mean ages were
40 ± 3 years.
Group II: Included 30 COPD patients, 26 males and 4
females and their mean ages were 52 ± 2.5 years.
COPD patients should fulﬁll the following criteria
Patients were non smokers or exsmokers (for at least 1 year)
and had a history of COPD. FEV1/FVC < 70%, % of recov-
ery after bronchodilator therapy is <15%, X-ray chest PA
view develops hyperinﬂation and X-ray chest ‘‘lateral view’’
showed retrosternal airspace >2.5 cm if measured form ante-
rior border of ascending aorta to posterior border of manu-
brium sterni.
Exclusion criteria were
If patients had bronchial asthma, other chronic lung diseases
or history of upper or lower respiratory tract infections in
the last month, history of vitamin D supplements within
1 month and acute exacerbation of COPD.
All persons were subjected to full history taking and full
clinical examination. Plain chest X ray (PA and lateral views),
Table 2 Mean, standard deviation and statistical analysis of serum level of 25-hydroxy vitamin D nmol/l in GI and GII.
GI GII t Test p Value
Serum level of 25-hydroxy vitamin D 181.32 ± 4.48 64.12 ± 3.61 62.33 0.001
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Figure 2 Mean, standard deviation and statistical analysis of
serum level of 25 hydroxy vitamin D nmol/l in GI and GII.
Does serum 25 hydroxy vitamin D level play a role in COPD? 45spirometry, and venous blood samples were taken for measure-
ment of serum levels of 25 hydroxy vitamin D, LL-37 and
IFNc. Measurement of 25 hydroxy vitamin D (expressed as
nmol/l) ‘‘using immunodiagnostic Enzyme-immuno-Assay
(EIA)’’ developed by immunodiagnostic bensheim and bio-
medical, wein, Australia catalog No. 02082005 25 OHvit
D6.DOC. LL-37 plasma level (expressed as ng/ml) was deter-
mined with ELISA kit (HK 321 humanLL-37 ELISA kit,
Hycult biotechnology uden. INFc (expressed as pg/ml) was
detected using the ELISA kit (Max Discovery TM human
interferon Gamma Bioscientiﬁc, USA, assay). Statistical pre-
sentation and analysis of the present study were conducted
using the mean, standard deviation and person correlation test
by SPSS. Written consent was taken from all persons taking
part in this study.
Results
Table 1 and Fig. 1 showed that mean values of actual value of
FEV1/FVC and percent of predicted FVC, FEV1, PEFR and
FEF 25–75% in group I was 100.9 ± 2.95, 96.76 ± 1.73,Table 3 Mean, standard deviation and statistical analysis of
serum level of LL-37 (ng/ml) in GI and GII.
GI GII t Test p Value
Serum level of LL-37 97.14 ± 1.80 25.36 ± 3.07 70.93 0.001
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Figure 3 Mean, standard deviation and statistical analysis of
serum level of LL-37(ng/ml) in GI and GII.97.6 ± 1.78, 96.3 ± 12.1 and 98.07 ± 1.56 respectively. The
mean values of actual value of FEV1/FVC and percent of pre-
dicted FVC, FEV1, PEFR and FEF 25–75% was
57.6 ± 14.34, 7.55 ± 6.48, 40.83 ± 6.35, 61.31 ± 6.85 and
61.35 ± 6.71 respectively. There was a signiﬁcant decrease in
all parameters in group II as compared to group I
(p< 0.05). Table 2 and Fig. 2 showed that mean values of ser-
um level of 25 hydroxy vitamin D in groups I and II were
181.32 ± 4.48 and 64.12 ± 3.61 respectively. There was a sig-
niﬁcant decrease in group II as compared to group I
(p< 0.05). Table 3 and Fig. 3 showed that mean values of ser-
um level of LL-37 in groups I and II were 97.14 ± 1.8 and
25.36 ± 3.07 ng/ml respectively. There was a signiﬁcant de-
crease in group II as compared to group I (p< 0.05). Table 4
and Fig. 4 showed that mean values of serum level of IFNc in
groups I and II were 14.35 ± 1.31 and 63.65 ± 7.95 pg/ml
respectively. There was a signiﬁcant increase in group II as
compared to group I (p< 0.05). Table 5 and Figs. 5–7 showed
that there was a signiﬁcant positive correlation between serum
level of 25 hydroxy vitamin D and both FEV1 and serum level
of LL-37 but there was a signiﬁcant negative correlation be-
tween serum level of 25 hydroxy vitamin D and serum level
of IFNc.
Discussion
In this study, there was vitamin D deﬁciency in COPD group
and FEV1 had a signiﬁcant positive correlation to 25 hydroxy
vitamin D level. Louise et al. concluded that COPD was asso-
ciated with an increased risk of vitamin D deﬁciency and
important disease characteristics were signiﬁcantly related to
25 hydroxy vitamin D levels especially FEV1 [10]. Black
et al. found a dose response relationship between 25 hydroxyTable 4 Mean, standard deviation and statistical analysis of
serum level of IFNc (pg/ml) in GI and GII.
GI GII t Test p Value
Serum level of IFNc 14.35 ± 1.31 63.65 ± 7.95 19.35 0.001
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Figure 4 Mean, standard deviation and statistical analysis of
serum level of IFNc (pg/ml) in GI and GII.
Table 5 Correlation between serum level of 25 hydroxy
vitamin D and serum levels of LL-37, IFNc and FEV1.
25-Hydroxy vitamin D
r p
Serum level of LL-37 0.863 0.001
Serum level of IFNc 0.745 0.001
FEV1 0.896 0.001
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Figure 5 Correlation between serum level of 25 hydroxy vitamin
D and serum level of LL-37.
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Figure 6 Correlation between serum level of 25 hydroxy vitamin
D and serum level of IFNc.
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46 B.I. El-Shafey, H.A. El-Srougyvitamin D and both FEV1 and FVC [2]. Janssens et al. showed
a nearly identical relationship between airway obstruction and
vitamin D level [11]. A similar association between 25 hydroxy
vitamin D and FEV1, has been reported in adults with asthma
[12].
Vitamin D has several functions, in addition to bone min-
eralization, vitamin D has been shown to be an important reg-
ulator of both elements of the immune system, has a role inF
Ddendritic cell maturation [13], T cell activation and prolifera-
tion [14] and Th1 T cell development [15], decrease the suscep-
tibility to respiratory infections, decrease the expression of
pro-inﬂammatory cytokines and chemokines [16]. Vitamin D
has been shown to directly affect processes involved in tissue
remodeling such as ﬁbroblast proliferation and collagen syn-
thesis and modulation of matrix metalloproteinase levels [17].
Undiagnosed osteoporosis leading to vertebral compression
may lead to loss in height, reduced rib cage mobility and de-
cline in pulmonary function [18]. Patients with COPD should
be considered at high risk of vitamin D insufﬁciency because
of reduction of outdoor activity, increased glucocorticoids in-
duced catabolism, impaired activation as a consequence of re-
nal dysfunction, and a lower storage capacity in muscle and fat
due to wasting [19]. Franco et al., concluded that severity of
COPD was related to low vitamin D level [20]. In contrast,
Bjerk et al., found that in severe COPD patients, 2000 iu of
daily vitamin D for 6 weeks increased 25 hydroxy vitamin D
level widely considered as normal, however, compared with
placebo, vitamin D supplementation has no discernible effect
on short physical performance Battery scorer and St. Georges
Respiratory question the naive score [21]. 1,25 dihydroxy vita-
min D is essential for induction of LL-37 through intracellular
vitamin D receptor as well as steroid receptor co-activator and
histone acetylation [22]. In our study, there was a decrease in
vitamin D level and LL-37 level which had several actions,
microbiocidal activity, suppressing the induction of TNFa,
IFN c and IL12p 40, inhibits formation of pseudomonas aer-
iginosa bioﬁlms, suppress of LPS-induced production of
inﬂammatory cytokines, neutrophils apoptosis which may play
a role in pathogenesis of COPD [23,9,24]. Lemire concluded
that active vitamin D metabolite 1,25 dihydroxy vitamin D3
promotes many of its actions through interaction with speciﬁc
intra cellular receptor located in monocytes and activated lym-
phocytes which leads to the concept that vitamin has a role in
immune system. Sterol inhibits lymphocyte proliferation and
immunoglobulin production in a dose-dependent fashion, at
a molecular level q,25-D3 inhibits the accumulation of MRNA
for IL-2, IFNc and GM-CSF [25] so, this study concluded that
vitamin D deﬁciency leads to reduction in lung functions in
Does serum 25 hydroxy vitamin D level play a role in COPD? 47COPD patients through its effect on serum levels of LL-37 and
IFNc and recommended that serum level of 25 hydroxy vita-
min D can be used in monitoring the severity of COPD and
vitamin D supplement may be beneﬁcial in COPD patients.
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